#Canada #Toronto #Triojection #SpinaFX Medical #lumbar disc treatment

SpinaFX Medical's CE Mark Certification: A New Horizon for Spine Treatment

SpinaFX Medical Inc., a Toronto-based innovator in the medical device industry, has recently made headlines by securing the CE Mark MDR certification for its flagship product, the Triojection® System. This milestone is set to significantly expand access to minimally invasive lumbar disc treatments across Europe and in various international markets where the CE mark is recognized.

The Triojection® System Explained

The Triojection® System represents a cutting-edge approach in spine care, utilizing an image-guided method to deliver a precisely controlled mixture of ozone and oxygen gas. This technique is specifically designed for intervertebral disc injections, catering to patients suffering from chronic pain due to lumbar disc herniation. Traditionally, patients who have not responded well to conservative treatments may face the daunting prospect of invasive surgical procedures, but with Triojection, the aim is to provide an alternative that minimizes recovery time and maximizes efficacy.

The system's unique capability lies in its combination of real-time image guidance and patented in-syringe spectroscopic measurement of ozone concentration. This allows healthcare professionals to perform intradiscal procedures with a level of precision that was not previously possible. Such advancements could lead to fewer patients requiring more extensive surgical interventions, which could alleviate the overall burden on healthcare systems.

Regulatory Foundations Supporting Advancement

The CE Mark MDR certification augments SpinaFX's already strong regulatory portfolio. The company maintains ISO 13485:2016 certifications in addition to having received Breakthrough Device Designation from the FDA for the Triojection® System in 2025. This designation indicates the FDA's recognition of the potential benefits the product can bring to patients, which is particularly promising given the rising demand for innovative medical solutions in spine care.

Dr. Kieran Murphy, the Chief Medical Officer and co-founder of SpinaFX, expressed excitement over the certification, stating, "Our CE Mark MDR certification for Triojection is another positive step towards expanding ozone-oxygen injection use across the world." This sentiment highlights the device's potential impact on pain management and the quality of life for patients suffering from persistent spinal issues.

New Market Opportunities

With the CE Mark certification secured, SpinaFX is now poised to begin commercial activities across 27 EU countries as well as 13 additional regions that recognize or accept this certification, including the UK, Switzerland, and parts of the Middle East and Asia. CEO John Soloninka emphasized that this development provides the company with the opportunity to generate revenue while also establishing a strong post-market evidence base in anticipation of further FDA trials in the U.S., which remains the largest market for intradiscal procedures.

Initial commercialization efforts will zero in on spine centers and pain management clinics, focusing on assisting a considerable population of patients who have not found relief through conventional treatment options. SpinaFX plans to support healthcare providers through comprehensive training programs and real-world data collection efforts to illustrate the clinical and economic benefits of intradiscal ozone-oxygen therapy.

Moving Forward

As Triojection remains categorized as an investigational device in the U.S., SpinaFX is prepared to proceed with clinical trials under an FDA-approved Investigational Device Exemption (IDE). The company aims to navigate the regulatory landscape systematically—seeking further market access for Triojection in various geographies in alignment with national requirements.

In conclusion, the CE Mark MDR certification marks not just a regulatory victory for SpinaFX Medical, but also serves as a beacon of hope for patients grappling with debilitating lumbar disc conditions. As the medical community continues to strive for effective, minimally invasive treatment options, SpinaFX is at the forefront of delivering solutions that could transform the future of spine care globally.